News
Pharma update – 17 August 2021 | Provisions judge denies preliminary order to carve out indications from marketing authorisation adalimumab biosimilar
In his decision of 16 July 2021 (published 5 August 2021) the Provisions Judge of the District Court of Amsterdam denied a preliminary order claimed by AbbVie Biotechnology Ltd (“AbbVie”) against Alvotech HF, Alvotech Swiss AG and Stada Arzneimittel AG (“Stada”) (collectively: “Alvotech et al.”) to carve-out AbbVie’s patented indications prior to launching their biosimilar
Read more ›
Silver for BarentsKrans in the IAM Patent 1000
The IAM Patent 1000 ‘The World’s Leading Patent Professionals 2021’ identifies the best patent specialists around the world. BarentsKrans has again secured a silver position this year as one of the world’s leading patent law firms. IAM Patent 1000 on BarentsKrans: Since its inception, BarentsKrans has provided game-changing support in complex disputes for global pioneers
Read more ›
Legal 500: splendid results for BarentsKrans
Legal 500 has published the 2021 rankings. The publication ranked BarentsKrans as a Top Tier Firm in Employment and Commercial Litigation. We also entered Tier 3 with Environment and Planning. Legal 500 is one of the most prominent guides on the international legal profession. Below you will find an overview of our rankings in the
Read more ›
Chambers Europe 2021 about BarentsKrans: ‘excellent service, impressive and helpful’
Last month we published the stunning results that BarentsKrans achieved in the Chambers 2021 Global edition. Meanwhile, the Chambers Europe guide has also been published and we would, once again, like to share our Chambers feedback with you. Chambers and Partners publishes her rankings annually and in doing so compares 52 jurisdictions across Europe, from
Read more ›
Chambers Global 2021 rankings: excellent results for BarentsKrans
Chambers Global 2021, the guide that provides a worldwide overview of international practice areas, has just been released. BarentsKrans received several honourable mentions. BarentsKrans has a number of wonderful mentions for Corporate/M&A, Intellectual Property and Dispute Resolution. Feedback from clients and peers The yearly Chambers ranking lists are based upon feedback received from clients as
Read more ›
Telecoms update | District Court rejects infringement claim
On 30 December 2020 (published 13 January 2021), the District Court of The Hague (“the Court”) rendered a judgment in final relief proceedings initiated by Adaptive Spectrum and Signal Alignment, Incorporated (“ASSIA”) against Koninklijke KPN N.V., Telfort Zakelijk B.V., XS4ALL Internet B.V., KPN B.V. (collectively “KPN”) and Nokia Solutions and Networks Nederland B.V. (“Nokia”) regarding
Read more ›
Legal 500: an overview of patent litigation in the Netherlands
BarentsKrans’ IP & Technology team provided an overview, in the form of an Q&A, of the most important aspects of patent procedures in The Netherlands for Legal 500. The Q&A provides for a view on the main questions about infringement and (un)validity of patents and important procedural information which is in particular relevant in an
Read more ›
Pharma update | Dutch Court of Appeal: Pemetrexed patent Eli Lilly valid and infringed
In its judgment of 27 October 2020, the Court of Appeal of The Hague found that the generic pemetrexed tromethamine product of Fresenius Kabi Nederland B.V. (“Fresenius”) infringes EP 1 313 508 (‘EP‘508’), held by Eli Lilly and Company (“Lilly”). Yet again a turn of events in Dutch case law, where this issue has been
Read more ›
Pharma update | AstraZeneca ordered to compensate damage health insurer Menzis for enforcing invalid patent
In a groundbreaking judgment of 14 October 2020, the District Court of The Hague ruled that AstraZeneca AB (‘AstraZeneca’) must compensate health insurer Menzis Zorgverzekeraar NV (‘Menzis’) for having enforced a patent that was later invalidated. AstraZeneca owned European patent EP 0 907 364 (“EP 364”) for a sustained-release (XR) formulation of quetiapine, an active
Read more ›
Pharma update | NPS’s cinacalcet patent held valid by Court of Appeal
EP ‘761, owned by Shire-NPS Pharmaceuticals Inc. (‘NPS’), relates to the API cinacalcet, which is used for the treatment of conditions of impaired regulation of calcium levels in human blood and tissue fluid. The product is marketed under the name Mimpara®. In September 2017, Accord Healthcare Ltd. and Accord Healthcare B.V. (‘Accord’) initiated invalidity proceedings
Read more ›
